CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Alemtuzumab

Last Updated: November 27, 2014
Result type: Reports
Project Number: SR0405-000
Product Line: Common Drug Review

Generic Name: Alemtuzumab

Brand Name: Lemtrada

Manufacturer: Genzyme Canada, a Division of Sanofi-Aventis Canada Inc.

Indications: Multiple Sclerosis, relapsing-remitting

Submission Type: New

Project Status: Complete

Date Recommendation Issued: June 18, 2015

Recommendation Type: List with criteria/condition